Previous 10 | Next 10 |
- Voyager’s TRACER TM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER - - Pipeline programs advancing; development candidate selections for lead p...
Voyager Therapeutics ( NASDAQ: VYGR ) is scheduled to announce Q3 earnings results on Tuesday, November 8th, before market open. The consensus EPS Estimate is -$0.43 (+35.8% Y/Y) and the consensus Revenue Estimate is $9.03M (+510.1% Y/Y). Over the last 3 months, EPS es...
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced it will report third quarter 2022 financial an...
- Data presented at European Society of Gene & Cell Therapy (ESGCT) Congress 2022 - - Receptor findings support potential for human translation of Voyager’s capsids and may help overcome barriers to CNS drug delivery - CAMBRIDGE, Mass., Oct. 11, 2022 (GLOBE NEWSWI...
Voyager Therapeutics ( NASDAQ: VYGR ) said it will get $10M after Pfizer ( NYSE: PFE ) exercised an option to license a adeno-associated virus (AAV) capsid for a potential gene therapy program for a rare neurologic disease target. AAV capsids are a type of deli...
Option exercise triggers $10 million payment to Voyager, further validating the potential of the TRACER capsid platform Voyager eligible for up to $290 million in associated development, regulatory, and commercial milestones, plus tiered royalties CAMBRIDGE, Mass., Oct....
CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that it will present three posters at the...
Peter Pfreundschuh has been appointed as CFO of Voyager Therapeutics ( NASDAQ: VYGR ), the gene therapy firm announced on Wednesday. Pfreundschuh has over 25 years of finance, business development, commercial and public company leadership experience in the life sciences an...
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced the appointment of Peter Pfreundschuh as Chie...
Voyager Therapeutics press release ( NASDAQ: VYGR ): Q2 GAAP EPS of -$0.50 misses by $0.02 . The company had collaboration revenue of $0.7 million for the second quarter of 2022, compared to $1.4 million for the same period in 2021. Cash, cash equivalents and marke...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...